

Invitation



CME-accredited satellite symposium

14th World Conference on Lung Cancer (WCLC) 2011

Supported by an educational grant from Daiichi Sankyo

c-MET – an important new target for lung cancer therapy

07.00 – 08.00: Tuesday 5th July, 2011

Elicium I, Amsterdam RAI, The Netherlands

Dear Colleague,

It is my great pleasure to invite you to the satellite symposium, 'c-MET – an important new target for lung cancer therapy', on Tuesday 5th July, 2011, during the World Congress in Lung Cancer (WCLC) in Amsterdam, The Netherlands.

Despite new chemotherapeutic regimens and targeted therapies, treatment outcomes in advanced or metastatic NSCLC remain unsatisfactory, with poor long-term survival rates. However, targeting c-MET-dependent neoplastic processes may provide a novel means for treating advanced NSCLC. This is supported by the fact that the c-MET signaling pathway has been implicated in the regulation of cancer cell growth, angiogenesis, invasion and metastasis. New data, particularly progression-free survival and overall survival data, from ongoing clinical trials using novel c-MET-inhibiting drugs have been encouraging.

This symposium will detail the c-MET signaling pathway in lung cancer and provide evidence for considering c-MET as a potential therapeutic target. It will also provide an overview of the many ongoing clinical trials evaluating c-MET-inhibiting drugs, and look at possible future directions in the evaluation of c-MET-driven malignancies.

I hope that you will be able to join myself and an outstanding faculty in Amsterdam for what promises to be an educational and highly informative session.

Alan B. Sandler
Chair

Passion & Precision

For Medicines – since 1899



Daiichi-Sankyo



CME-accredited satellite symposium

14th World Conference on Lung Cancer (WCLC) 2011

Supported by an educational grant from Daiichi Sankyo

c-MET – an important new target for lung cancer therapy

07.00 – 08.00: Tuesday 5th July, 2011

Elicium I, Amsterdam RAI, The Netherlands

Breakfast boxes and refreshments will be available before the symposium

07.00 INTRODUCTION

Alan B. Sandler, Division of Hematology and Medical Oncology,
Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA

07.05 c-MET BIOLOGY IN LUNG CANCER

Patrick C. Ma, Cleveland Clinic Lerner College of Medicine of Case Western
Reserve University and Cleveland Clinic Taussig Cancer Institute, Ohio, USA

07.20 c-MET INHIBITORS: CLINICAL DATA AND ONGOING STUDIES

Alan B. Sandler

07.35 c-MET-DRIVEN MALIGNANCIES: FUTURE DIRECTIONS AND OUTLOOK

Johan Vansteenkiste, Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium

07.50 Q&A

All

07.55 CONCLUSIONS

Alan B. Sandler

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of CMI Education Institute and Springer Healthcare. CMI Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

CMI Education Institute designates this educational live activity for a maximum of 1.0 *AMA PRA category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

International Physicians are formally eligible for *AMA PRA Category 1 Credit*[™].

For physician assistants, AAPA accepts Category 1 Credit from AOACCME, Prescribed credit from AAFP, and *AMA PRA Category 1 Credit*[™] for the PRA from organizations accredited by ACCME.

This presentation was selected by the 14th World Conference on Lung Cancer Programme Committee as an independent educational activity held in conjunction with the 14th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by the IASLC.